Muscle strength in breast cancer patients receiving different treatment regimes
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Muscle dysfunction and sarcopenia have been associated with poor performance status, an increased mortality risk, and greater side effects in oncologic patients. However, little is known about how performance is affected by cancer therapy. We investigated muscle strength in breast cancer patients in different adjuvant treatment settings and also compared it with data from healthy individuals. Methods: Breast cancer patients ( N = 255) from two randomized controlled exercise trials, staged 0–III and aged 54.4 ± 9.4 years, were categorized into four groups according to their treatment status. In a cross‐sectional design, muscle function was assessed bilaterally by isokinetic dynamometry (0°, 60°, 180°/s) as maximal voluntary isometric contraction (MVIC) and maximal isokinetic peak torque (MIPT) in shoulder rotators and knee flexors and extensors. Additionally, muscular fatigue index (FI%) and shoulder flexibility were evaluated. Healthy women ( N = 26), aged 53.3 ± 9.8 years, were tested using the same method. Analysis of covariance was used to estimate the impact of different cancer treatments on skeletal muscle function with adjustment for various clinical and socio‐demographic factors. Results: Consistently, lower muscle strength was measured in shoulder and knee strength in patients after chemotherapy. On average, patients had up to 25% lower strength in lower extremities and 12–16% in upper extremities in MVIC and MIPT during cancer treatment compared with healthy women. No substantial difference between patient groups in shoulder strength, but significantly lower shoulder flexibility in patients with radical mastectomy was measured. Chemotherapy‐treated patients had consistently higher FI%. No serious adverse events were reported. Conclusions: Breast cancer patients showed markedly impaired muscle strength and joint dysfunctions before and after anticancer treatment. The significant differences between patients and healthy individuals underline the need of exercise therapy as early as possible in order to prevent or counteract the loss of muscle function after curative surgery as well as the consequences of neo‐/adjuvant chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238 · cited 2×
“Sarcopenia is an independent predictor of survival, which is closely related to patients’ functional status and potentially to CT toxicity.(38,39) In average, nearly all evaluated BC groups in our study had indications for sarcopenia because of impaired muscle strength and function,(40) and those who had received CT i…”
Newman, A. B., Kupelian, V., Visser, M., Simonsick, E. M., Goodpaster, B. H., Kritchevsky, S. B., Tylavsky, F. A., Rubin, S. M., Harris, T. B., & on Behalf of the Health, A. A. B. C. S. I. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.1.72 · Cited by 1,692 · cited 1×
“With regard to healthy older individuals, muscle strength, but not mass, was identified as a strong independent predictor of all-cause mortality.(9) Based on the current knowledge of treatment-related side effects, it can be assumed that muscle function is affected by different cancer treatments.”
Courneya, K. S., Segal, R. J., Mackey, J. R., Gelmon, K., Reid, R. D., Friedenreich, C. M., Ladha, A. B., Proulx, C., Vallance, J. K. H., Lane, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2024 · Cited by 1,179
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., Mackey, J. R., Koski, S., Pituskin, E., & Sawyer, M. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2242 · Cited by 1,104 · cited 3×
“Furthermore, it was shown that skeletal muscle status is of clinical relevance because it is associated with treatment complications and time-to-tumour progression.(8) With regard to healthy older individuals, muscle strength, but not mass, was identified as a strong independent predictor of all-cause mortality.”
A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women
Frontera, W. R., Hughes, V. A., Lutz, K. J., & Evans, W. J. (1991) · Journal of Applied Physiology · doi:10.1152/jappl.1991.71.2.644 · Cited by 1,011 · cited 1×
“Nevertheless, the strength performance of our healthy participants was in line with comparably aged healthy women.(49) We also found significant age differences between the treatment groups showing a higher age in the non-CT group.”
Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic Review
Ballard-Barbash, R., Friedenreich, C. M., Courneya, K. S., Siddiqi, S. M., McTiernan, A., & Alfano, C. M. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs207 · Cited by 831
van Waart, H., Stuiver, M. M., van Harten, W. H., Geleijn, E., Kieffer, J. M., Buffart, L. M., de Maaker-Berkhof, M., Boven, E., Schrama, J., Geenen, M. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1081 · Cited by 644
Schmid, D., & Leitzmann, M. F. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu012 · Cited by 625
Cited by
Hand grip strength as a proposed new vital sign of health: a narrative review of evidences
Vaishya, R., Misra, A., Vaish, A., Ursino, N., & D’Ambrosi, R. (2024) · Journal of Health, Population and Nutrition · doi:10.1186/s41043-024-00500-y · Cited by 385
“On average, patients had up to 25% lower strength in their lower extremities and 12–16% in their upper extremities, during cancer treatment compared with healthy women [116].”
Background
Metadata
- Authors
- Klassen, O., Schmidt, M. E., Ulrich, C. M., Schneeweiss, A., Potthoff, K., Steindorf, K., & Wiskemann, J.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2016-11-28
- Volume
- 8
- Issue
- 2
- Pages
- 305-316
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2557299371
- Cited by
- 232
- References
- 47
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.